哈三联业绩预告首度年度亏损，股价大幅低开

Core Viewpoint - The company, Ha San Lian, has disclosed significant information indicating a projected net profit loss for the first time, primarily due to policy impacts and increased expenses [1][4]. Recent Events - On February 6, 2026, the company announced the completion of a partial repurchase and cancellation of restricted stock, which may affect its equity structure [2]. Shareholder Information - As of January 30, 2026, the number of shareholders was reported to be 35,661, showing a change from previous periods [3]. Performance Overview - The company forecasts a net profit loss between 315 million to 375 million yuan for 2025, representing a year-on-year decline of 636.85% to 739.11%, marking its first annual loss. Additionally, the expected operating revenue is 790 million yuan, down 30% year-on-year. The performance decline is attributed to the drug procurement policy leading to lower sales prices, increased period expenses, and asset impairment provisions [4]. - On the same day, the company announced an asset impairment loss of approximately 59.49 million yuan and wrote off certain assets, which will collectively reduce the 2025 net profit by about 79.39 million yuan [4]. Stock Performance - On January 29, 2026, the stock price significantly dropped by 7.84% in response to the earnings forecast, reflecting market concerns over the deteriorating performance [5].